 NEW YORK, Dec. 03, 2020 GLOBE NEWSWIRE -- Protara Therapeutics, Inc. Nasdaq: TARA, a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 41,500 shares of common stock to two new employees. 